Recent Posts
Featured Posts

Who Benefits from Herceptin and Other Anti-HER2 Cancer Therapies?

HER2-positive breast cancer may be a misnomer, according to a growing body of evidence that one of the most widely recognized oncogenes, HER2, may not be the primary driver of the disease. The research, which comes from several groups including Genentech, makers of the prevailing anti-HER2 treatment, has researchers questioning whether current clinical guidelines for classifying and treating breast cancer may be off the mark. New classification schemes may better identify those patients more likely to benefit from anti-HER2 treatment, or point to therapies that might be more effective.


Search By Tags
  • Facebook - White Circle
  • Twitter - White Circle
  • Instagram - White Circle
  • LinkedIn - White Circle

Connect with us on social media

© 2021 Care For A Cure, Inc. is a non-profit organization

with a 501(c)(3) tax exempt status. All rights reserved.